CIT Safety and Health Research Laboratories and Stemina Biomarker Discovery have formed a partnership.

CIT will distribute Stemina’s devTOX assay in Europe and will work with Stemina to validate the test for use under the REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) initiative. As early as 2012, REACH will require manufacturers and importers to register and test all chemicals and compositions containing chemicals.
 
DevTOX uses human Embryonic Stem (hES) cells to test pharmaceuticals, chemicals and formulations.  DevTOX models human developmental toxicity with about 90% accuracy. CIT specializes in preclinical development of pharmaceuticals, chemicals and consumer products.